Royalty Pharma and J&J partner to develop autoimmune treatment
Published on March 30, 2026.
Royalty Pharma (RPRX.O) has signed a $500 million research and development agreement with Johnson & Johnson (JNJ.N) to develop an experimental antibody treatment for autoimmune diseases. The agreement will cover 2026 and 27 years and will support the development of JNJ-4804, an experimental co-antibody therapy that targets the two immune pathways involved in autoimmune inflammation. Shares of Royalty Pharma rose by 1.4% in premarket trading.
Related Articles
Global first-quarter M&A exceeds $1.2 trillion, led by AI
Global M&A activity surged to $1.2 trillion in the first quarter, led by AI wins and cross-border transactions, despite market volatility and economic challenges.
UK food inflation heading towards 10% due to Iran war, industry says
The UK Food and Drink Federation predicts food inflation will rise to 10% by 2026 due to the Iran war, despite industry efforts to avoid price increases.
Crypto asset manager CoinShares (CSHR) to list on Nasdaq after $1.2 billion SPAC deal
CoinShares is set to list on the Nasdaq under the same name as Apple, following a $1.2 billion merger with Vine Hill Capital Investment Corp.